Tuesday, August 09, 2016 8:45:47 AM
Currently, GW Pharma has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings:
GW Pharma reported a narrower-than-expected loss in the third quarter of fiscal 2016. Our consensus called for a loss of $1.73 per share and the company reported a loss of 73 cents.
Revenues:
However, revenues fell short of expectations. GW Pharma posted revenues of $3.1 million, compared to our consensus estimate of $3.4 million.Key Stats: GW Pharma expects to seek FDA approval for Epidiolex for both Dravet syndrome and LGS indications in the first half of fiscal 2017.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM